COVID-19 paper is UNMC's most-cited of 2020

by Kalani Simpson, UNMC strategic communications | January 27, 2021

Image with caption: Siddappa Byrareddy, PhD,

Siddappa Byrareddy, PhD,

A paper outlining a new, emerging infectious disease -- COVID-19 -- was UNMC's most cited scientific publication of 2020. "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak," co-authored by Siddappa Byrareddy, PhD, associate professor and vice chair of research, pharmacology and experimental neuroscience, has been cited more than 1,000 times, and counting.

That's not surprising, said Jennifer Larsen, MD, vice chancellor for research. Dr. Byrareddy's article is a great resource that brought together information other scientists were looking for in 2020, all in one place and easy to read.

"Almost always," she said, "review articles and guidelines are the most cited because they appeal to a broad audience."

What might we expect to see in a list of most cited research?

After review articles, "Next comes large clinical trials, of course," Dr. Larsen continued. "For the same reason. And those show up here, too."

Andre Kalil, MD, professor of infectious disease, who headed UNMC's efforts in the first National Institutes of Health trial to evaluate experimental COVID-19 treatments, focusing on the anti-viral drug remdesivir, shows up twice in the top five.

"Most seminal basic science isn't recognized until long after it's published, at least by citation index," Dr. Larsen said. "Because anything revolutionary isn't immediately embraced."

But it is informative to see which papers and manuscripts, with UNMC authors and contributors, were most cited by their colleagues across the world in 2020.

Like a COVID-19 test result, citation numbers are but a snapshot in time, and may be different today than they were when recorded for this story.

That said, the following are the top five most cited UNMC publications this past year:

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

  • Journal of Autoimmunity
  • Siddappa Byrareddy, PhD, associate professor and vice chair of research, pharmacology and experimental neuroscience, as second author
  • "In this review, we highlight the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease."
  • Cited by 1,025 documents

Remdesivir for the treatment of COVID-19 - Final report

  • New England Journal of Medicine
  • Andre Kalil, MD, professor of infectious disease, among many other authors and ACTT-1 Study Group members
  • "Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection."
  • Cited by 750 documents

Pan-cancer analysis of whole genomes

  • Nature
  • Tony Hollingsworth, PhD, Hunt Chair in Cancer Research, and Sarah Thayer, MD, PhD, chief of surgical oncology, among many members of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium
  • "A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation; analyses timings and patterns of tumor evolution; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity; and evaluates a range of more-specialized features of cancer genomes."
  • Cited by 183 documents

Treating COVID-19 - Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials during Pandemics

  • Journal of the American Medical Association (JAMA)
  • Andre Kalil, MD, professor of infectious disease
  • "This unprecedented speed from concept to implementation in just a few weeks is noteworthy and provides proof that clinical trials can be promptly initiated even in the middle of a pandemic. The rapid and simultaneous combination of supportive care and RCTs is the only way to find effective and safe treatments for COVID-19 and any other future outbreak."
  • Cited by 154 documents

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial

  • Journal of Thrombosis and Haemostasis
  • Krishna Gundabolu, MBBS, assistant professor of oncology and hematology, as one of multiple authors.
  • "Oral apixaban was associated with low major bleeding and cancer-associated venous thromboembolism (VTE) recurrence rates for the treatment of VTE in cancer patients."
  • Cited by 77 documents


Fill out the following and your comment will post once it has been approved.

Name (Required)

Email (Required)

Thank you, your comment will appear below once it has been approved.

Shirish Joshi.
January 28, 2021 at 9:42 AM

Congratulations Dr. Siddappa, well done.

Kusum Kharbanda
January 27, 2021 at 10:24 PM

Congratulations Sid!

Samikkannu Thangavel
January 27, 2021 at 3:06 PM

Congratulations Dr. Siddappa.

Beth Beam
January 27, 2021 at 8:51 AM

Congratulations Sid! Well done sir.

January 27, 2021 at 8:11 AM

Congrats sir

January 27, 2021 at 8:06 AM

Congrats sir

Dr. Vijay Singu
January 27, 2021 at 6:12 AM

Congratulations Dr. Siddappa.